Total Payments
$237,373
2024 Payments
$2,143
Companies
23
Transactions
126
Medicare Patients
2,248
Medicare Billing
$301,867
Payment Breakdown by Category
Research$220,255 (92.8%)
Consulting$11,835 (5.0%)
Travel$3,285 (1.4%)
Food & Beverage$1,999 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $220,255 | 42 | 92.8% |
| Consulting Fee | $11,835 | 16 | 5.0% |
| Travel and Lodging | $3,285 | 14 | 1.4% |
| Food and Beverage | $1,999 | 54 | 0.8% |
Payments by Type
Research
$220,255
42 transactions
General
$17,118
84 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Valneva Austria GmbH | $109,211 | 4 | $0 (2022) |
| Glenmark Pharmaceuticals Inc. | $47,898 | 12 | $0 (2018) |
| Lupin Inc. | $39,760 | 6 | $0 (2018) |
| Eli Lilly and Company | $18,332 | 9 | $0 (2022) |
| CSL Behring | $11,835 | 16 | $0 (2018) |
| PFIZER INC. | $4,469 | 14 | $0 (2023) |
| SANOFI PASTEUR INC. | $1,979 | 9 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $1,608 | 12 | $0 (2018) |
| AstraZeneca UK Limited | $1,587 | 10 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $139.69 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,143 | 16 | SANOFI PASTEUR INC. ($1,979) |
| 2023 | $3,232 | 10 | PFIZER INC. ($3,138) |
| 2022 | $110,324 | 21 | Valneva Austria GmbH ($109,211) |
| 2021 | $4,378 | 8 | Eli Lilly and Company ($4,263) |
| 2020 | $12,675 | 5 | Eli Lilly and Company ($12,675) |
| 2019 | $1,828 | 8 | PFIZER INC. ($1,183) |
| 2018 | $57,971 | 39 | Lupin Inc. ($39,760) |
| 2017 | $44,821 | 19 | Glenmark Pharmaceuticals Inc. ($35,416) |
All Payment Transactions
126 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/26/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $78.00 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/26/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $49.60 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/26/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $40.00 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/26/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $40.00 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/25/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $955.40 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/25/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $475.26 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/25/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $152.41 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/25/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $108.54 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/25/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $80.00 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/14/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: Inflammation | ||||||
| 10/03/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $21.08 | General |
| Category: HIV | ||||||
| 09/20/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $30.02 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 07/15/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: RESPIRATORY | ||||||
| 03/20/2024 | Abbott Laboratories | FREESTYLE LIBRE 2 (Device) | Food and Beverage | In-kind items and services | $27.88 | General |
| Category: Diabetes Care | ||||||
| 03/04/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Inflammation | ||||||
| 02/12/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: Diabetes | ||||||
| 10/20/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: Inflammation | ||||||
| 06/23/2023 | PFIZER INC. | COMIRNATY (Biological), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: VACCINES | ||||||
| 06/02/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: INSOMNIA | ||||||
| 05/15/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: Diabetes | ||||||
| 05/12/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $21.95 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 04/26/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 04/26/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $574.75 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 02/13/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 01/20/2023 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $17.91 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | Valneva Austria GmbH | $109,211 | 4 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $39,760 | 6 |
| GSP304-201 | Glenmark Pharmaceuticals Inc. | $35,416 | 7 |
| Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Glenmark Pharmaceuticals Inc. | $12,482 | 5 |
| PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | Eli Lilly and Company | $8,582 | 3 |
| A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | Eli Lilly and Company | $8,000 | 3 |
| A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | PFIZER INC. | $3,075 | 2 |
| A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | SANOFI PASTEUR INC. | $1,979 | 9 |
| PHASE 1, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, TRIPLE-BLIND, SINGLE-ASCENDING DOSE AND REPEAT-DOSE TRIAL IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ATOPIC DERMATITIS | Eli Lilly and Company | $956.75 | 2 |
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $793.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 544 | 965 | $129,233 | $70,663 |
| 2022 | 10 | 533 | 991 | $131,643 | $73,488 |
| 2021 | 10 | 509 | 1,003 | $146,719 | $76,717 |
| 2020 | 14 | 662 | 1,298 | $132,924 | $80,998 |
Total Patients
2,248
Total Services
4,257
Medicare Billing
$301,867
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 150 | 415 | $69,122 | $35,832 | 51.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 106 | 218 | $25,593 | $13,424 | 52.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 89 | 89 | $15,082 | $11,385 | 75.5% |
| 99349 | Residence visit for established patient with moderate level of medical decision making, per day, if using time, at least 40 minutes | Office | 2023 | 12 | 49 | $8,045 | $4,334 | 53.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $6,928 | $2,968 | 42.8% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 91 | 91 | $2,161 | $1,665 | 77.1% |
| 20552 | Injection of trigger points, 1-2 muscles | Office | 2023 | 20 | 23 | $1,630 | $843.80 | 51.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 21 | 21 | $401.10 | $190.49 | 47.5% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 23 | 27 | $270.00 | $20.85 | 7.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 167 | 484 | $81,215 | $42,333 | 52.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 95 | 178 | $20,897 | $11,376 | 54.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 75 | 75 | $12,710 | $9,952 | 78.3% |
| 99349 | Established patient home visit, typically 40 minutes | Office | 2022 | 12 | 44 | $7,224 | $3,931 | 54.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $4,114 | $2,449 | 59.5% |
| 20552 | Injection of trigger points, 1-2 muscles | Office | 2022 | 29 | 35 | $2,425 | $1,520 | 62.7% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 79 | 79 | $1,876 | $1,471 | 78.4% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 18 | 27 | $415.00 | $260.32 | 62.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 13 | 15 | $297.96 | $163.38 | 54.8% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 26 | 35 | $470.00 | $31.50 | 6.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 171 | 536 | $88,694 | $47,040 | 53.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 64 | 64 | $11,220 | $8,676 | 77.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 81 | 144 | $17,687 | $8,585 | 48.5% |
| 99349 | Established patient home visit, typically 40 minutes | Office | 2021 | 16 | 50 | $10,116 | $4,987 | 49.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 40 | 40 | $8,880 | $4,493 | 50.6% |
| G0444 | Annual depression screening, 15 minutes | Office | 2021 | 58 | 58 | $2,351 | $1,102 | 46.9% |
About Michael Jacobs, M.D., PH.D
Michael Jacobs, M.D., PH.D is a Internal Medicine healthcare provider based in Las Vegas, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1053300913.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Michael Jacobs, M.D., PH.D has received a total of $237,373 in payments from pharmaceutical and medical device companies, with $2,143 received in 2024. These payments were reported across 126 transactions from 23 companies. The most common payment nature is "" ($220,255).
As a Medicare-enrolled provider, Jacobs has provided services to 2,248 Medicare beneficiaries, totaling 4,257 services with total Medicare billing of $301,867. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine
- Location Las Vegas, NV
- Active Since 10/13/2005
- Last Updated 08/23/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1053300913
Products in Payments
- TIOTROPIUM (Drug) $39,760
- NURTEC ODT (Drug) $3,075
- MK-7264 (Drug) $1,608
- ELIQUIS (Drug) $193.45
- CONTRAVE (Drug) $96.22
- Otezla (Drug) $63.82
- MOUNJARO (Drug) $50.08
- BREZTRI (Drug) $35.37
- LONHALA MAGNAIR (Drug) $33.41
- Rybelsus (Drug) $32.73
- Yupelri (Drug) $31.82
- FreeStyle Libre 2 (Device) $30.27
- YUPELRI (Drug) $30.02
- FREESTYLE LIBRE 2 (Device) $27.88
- TRELEGY ELLIPTA (Drug) $24.56
- OFEV (Drug) $23.05
- QUVIVIQ (Drug) $22.79
- APRETUDE (Biological) $21.08
- Dexcom G6 Transmitter (Medical Supply) $18.35
- COMIRNATY (Biological) $17.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Las Vegas
Fadi Braiteh, M.d, M.D
Internal Medicine — Payments: $4.0M
Internal Medicine $4.0M
Samer Nakhle, Md, MD
Internal Medicine — Payments: $911,236
Internal Medicine $911,236
Maxine Ingham, Md, MD
Internal Medicine — Payments: $602,393
Internal Medicine $602,393
Richard Cottiero, Md, MD
Internal Medicine — Payments: $289,614
Internal Medicine $289,614
Dr. Kevin Dunsmoor, Do, DO
Internal Medicine — Payments: $197,836
Internal Medicine $197,836
Dr. Filippo Cremonini, Md, MD
Internal Medicine — Payments: $169,922
Internal Medicine $169,922